COMPARATIVE CLINICAL STUDY OF IMIPENEM/CILASTATIN SODIUM AND CEFTIZOXIME IN THE TREATMENT OF PURULENT PERITONITIS
1986 Volume 34 Issue 8 Pages 713-738
Details
1986 Volume 34 Issue 8 Pages 713-738
A comparative study was performed by a well-controlled method to objectively evaluate: the efficacy safety and utility of imipenem/cilastatin sodium (IPM/CS) compared with ceftizoxime (CZX) in the treatment of purulent peritonitis. IPM/CS and CZX were administered by an intravenousidrip infusion in a daily dose of 1g/1g and 2g, respectively. The following results were obtained.
1. Clinical efficacy rate was 77.8%(49/63) in IPM/CS group and 77.8%(49/63) in CZX group.
2. Final overall clinical improvement rate was 93.7%(59/63) in IPM/CS group and 87.5%(56/64) in CZX group, with no statistically significant difference between the two groups.
3. As for bacteriological effect, the eradication rate in evaluable patients was 87.5%(42/48) in IPM/CS group and 77.3%(34/44) in CZX group, with no statistically significant difference between the two groups. In bacteriological response, the eradication rate was 96.5%(109/113) in IPM/CS group and 95.4%(103/108) in CZX group, with also no statistically significant difference between the two groups.
4. Side effects were observed in 1 of 72 patients (1.4%) in IPM/CS group and 2 of 71 patients (2.8%) in CZX group, whereas abnormal laboratory findings were observed in 12 of 70 patients (17.1%) in IPM/CS group and 10 of 71 patients (14.1%) in CZX group, respectively. In the incidences of adverse effects and abnormal laboratory findings, there was no statistically significant difference between the two groups.
5. Overall clinical utility rate was 79.4%(50/63) in IPM/CS group and 76. 6%(49/64) in CZX group, with no statistically significant difference between the two groups.
It will be considered that these results suggests IPM/CS is a useful drug in the treatment of purulent peritonitis as well as CZX.
